+ A
A -
Tribune News Network
Doha
Dr Nashiru Billa, professor of Pharmaceutical Sciences at the College of Pharmacy, QU, kicked off a study on colon cancer and the ability of curcumin to prevent it. The study, titled ‘Colon cancer targeted muco-adhesive and muco-penetrative nano-formulation of curcumin’, was aided by a QU International Research Collaboration Co-fund grant worth $121,680.
This research endeavour is motivated by the fact that colon cancer is the third most common type of cancer worldwide, while it is largely preventable through lifestyle modifications. This statistic is closely mirrored in Qatar and likely to worsen due to the COVID 19 restrictions, among other factors. Chemotherapy is the mainstay treatment option in managing colon cancer, with surgery or radiation administered depending on the severity of the disease.
The side effects associated with chemotherapy can be very severe or even fatal. There is thus a quest for safer, yet effective treatment options. Curcumin, obtained from the Indian spice, turmeric, has been the subject of intense research in the past decade, largely due to the low incidence of colon cancer among natives of the sub-Indian continent. Several in-vitro and in-vivo studies point to the anti-colon cancer effects of curcumin, with potentially minimal side effects. However, it is poorly soluble and hence presents sub-therapeutic concentrations when administered orally unless some form of chemical modification or formulation intervention is imparted.
Nanoparticle formulations have the ability to traverse tissue, especially, actively diving tissues like cancer tissue. Therefore, through appropriate formulation approaches, it is possible to deploy curcumin into colon cancer tissue so that its effects are enhanced without the associated side effects akin to chemotherapy.
Thus, the main aim of the study was to potentiate the anti-colon cancer effects of curcumin through nano-formulation. The nano-particles would comprise of chitosan (obtained from chitin, the major constituent of the exoskeleton of arthropods) and modified citrus pectin (from rind of citrus fruits) and expected to be deployed to the colon following oral administration as a muco-adhesive and muco-penetrative delivery system for curcumin. The chitosan is expected to impart mucoadhesion to colon tissue, while the modified citrus pectin is expected to retain the integrity of the nanoparticles when administered orally and also impart anticancer effects after caecal arrival. A key feature within this research endeavour worth highlighting is the use of naturally obtained excipients used in the formulation of nanoparticles, which may not only contribute to minimising side effects from curcumin but may also be acceptable to colon cancer patients in Qatar and other stakeholders.
This international collaborative grant would be executed along with Dr Syahril Abdulla of the University of Putra, Malaysia. Drs Billa and Syahril have previously secured a number of grants and co-supervised students. The Qatar University collaborators include Drs Hesham Korashy and Mohamed Izham.
Doha
Dr Nashiru Billa, professor of Pharmaceutical Sciences at the College of Pharmacy, QU, kicked off a study on colon cancer and the ability of curcumin to prevent it. The study, titled ‘Colon cancer targeted muco-adhesive and muco-penetrative nano-formulation of curcumin’, was aided by a QU International Research Collaboration Co-fund grant worth $121,680.
This research endeavour is motivated by the fact that colon cancer is the third most common type of cancer worldwide, while it is largely preventable through lifestyle modifications. This statistic is closely mirrored in Qatar and likely to worsen due to the COVID 19 restrictions, among other factors. Chemotherapy is the mainstay treatment option in managing colon cancer, with surgery or radiation administered depending on the severity of the disease.
The side effects associated with chemotherapy can be very severe or even fatal. There is thus a quest for safer, yet effective treatment options. Curcumin, obtained from the Indian spice, turmeric, has been the subject of intense research in the past decade, largely due to the low incidence of colon cancer among natives of the sub-Indian continent. Several in-vitro and in-vivo studies point to the anti-colon cancer effects of curcumin, with potentially minimal side effects. However, it is poorly soluble and hence presents sub-therapeutic concentrations when administered orally unless some form of chemical modification or formulation intervention is imparted.
Nanoparticle formulations have the ability to traverse tissue, especially, actively diving tissues like cancer tissue. Therefore, through appropriate formulation approaches, it is possible to deploy curcumin into colon cancer tissue so that its effects are enhanced without the associated side effects akin to chemotherapy.
Thus, the main aim of the study was to potentiate the anti-colon cancer effects of curcumin through nano-formulation. The nano-particles would comprise of chitosan (obtained from chitin, the major constituent of the exoskeleton of arthropods) and modified citrus pectin (from rind of citrus fruits) and expected to be deployed to the colon following oral administration as a muco-adhesive and muco-penetrative delivery system for curcumin. The chitosan is expected to impart mucoadhesion to colon tissue, while the modified citrus pectin is expected to retain the integrity of the nanoparticles when administered orally and also impart anticancer effects after caecal arrival. A key feature within this research endeavour worth highlighting is the use of naturally obtained excipients used in the formulation of nanoparticles, which may not only contribute to minimising side effects from curcumin but may also be acceptable to colon cancer patients in Qatar and other stakeholders.
This international collaborative grant would be executed along with Dr Syahril Abdulla of the University of Putra, Malaysia. Drs Billa and Syahril have previously secured a number of grants and co-supervised students. The Qatar University collaborators include Drs Hesham Korashy and Mohamed Izham.
